Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
taVNS in Dry Eye Disease With Meibomian Gland Dysfunction
NCT06544447Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Ocular Surface Disease Index at 6 months. Started Jun 2021; status: recruiting.
Beyond the preview
Go deeper on NCT06544447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544447.